Due to their important regulatory roles, receptor tyrosine kinases (RTKs) are common targets in cancer treatments and there are numerous small-molecular inhibitor and monoclonal antibodies targeting RTKs currently used in the clinic. It’s becoming increasingly clear that TAM receptors, like several commonly targeted RTKs, have a role in the development of various cancers and, as such, the development of therapeutics targeting these receptors has become a topic of interest. Working in a collaborative project with teams at UNC, we are using structure to guide the design of various types of therapies that inhibit or degrade TAM receptors.
